leisure time -WSS

leisure time

author：comprehensive 2025-09-28 00:50:03 - browse：14

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： H5N1 virus can be tracked in retail milk, scientists say

explore

WSS

Bird flu surveillance in wastewater gets boost from consortium

The system is set up to fail children with medical complexity

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

California wildfire smoke linked to 52,000 early deaths, study says

Cigna wins case to block Amy Bricker's move to CVS

Study finds gene variants tied to breast cancer risk in Black women

focus

leisure time

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Making the case for fair compensation in clinical trials

23andMe had bad news about my health. I wish a person had delivered it

Statins may not be needed by millions of people, study suggests

Cancer drug shortages should be causing more outrage

Digital health: a case of mistaken identity

Anesthesiologist group: stop taking Ozempic before surgery

Making the case for fair compensation in clinical trials

Heart attack and stroke risk calculators need revising

Digital health: a case of mistaken identity

Wikipedia

Liver decline slowed by off

Teladoc has a new CEO, but challenges remain the same

Making the case for fair compensation in clinical trials

Digital health: a case of mistaken identity

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

UnitedHealth argues against case alleging wrongful AI care denials

explore

leisure time

hotspot

focus